- Record: found
- Abstract: not found
- Article: not found
Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients
Aparna R. Parikh ,
Emily E. Van Seventer ,
Giulia Siravegna ,
Anna V Hartwig ,
Ariel Jaimovich ,
Yupeng He ,
Katie Kanter ,
Madeleine Fish ,
Kathryn D Fosbenner ,
Benchun Miao ,
Susannah Phillips ,
John H Carmichael ,
Nihaarika Sharma ,
Joy Jarnagin ,
Islam Baiev ,
Yojan S Shah ,
Isobel J Fetter ,
Heather A Shahzade ,
Jill N Allen ,
Lawrence S Blaszkowsky ,
Jeffrey W Clark ,
Jon S Dubois ,
Joseph W Franses ,
Bruce Giantonio ,
Lipika Goyal ,
Samuel J Klempner ,
Ryan D Nipp ,
Eric J Roeland ,
David P Ryan ,
Colin D Weekes ,
Jennifer Y Wo ,
Theodore S Hong ,
Liliana Bordeianou ,
Cristina R Ferrone ,
Motaz Qadan ,
Hiroko Kunitake ,
David Berger ,
Rocco Ricciardi ,
James C Cusack ,
Victoria M Raymond ,
AmirAli Talasaz ,
Genevieve M Boland ,
Ryan B Corcoran
April 29 2021
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d1505873e439">Detection of persistent circulating tumor DNA (ctDNA)
after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur.
Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations
to facilitate ctDNA detection, requiring tumor and blood. We evaluated a plasma-only
ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed
MRD detection.
</p>